![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SRSF4 |
Gene summary for SRSF4 |
![]() |
Gene information | Species | Human | Gene symbol | SRSF4 | Gene ID | 6429 |
Gene name | serine and arginine rich splicing factor 4 | |
Gene Alias | SFRS4 | |
Cytomap | 1p35.3 | |
Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | Q08170 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6429 | SRSF4 | CA_HPV_1 | Human | Cervix | CC | 2.66e-02 | -1.96e-02 | 0.0264 |
6429 | SRSF4 | CCI_1 | Human | Cervix | CC | 4.30e-02 | 6.94e-01 | 0.528 |
6429 | SRSF4 | CCI_3 | Human | Cervix | CC | 1.27e-11 | 8.81e-01 | 0.516 |
6429 | SRSF4 | sample3 | Human | Cervix | CC | 5.73e-03 | 1.96e-01 | 0.1387 |
6429 | SRSF4 | T3 | Human | Cervix | CC | 2.67e-05 | 2.04e-01 | 0.1389 |
6429 | SRSF4 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.14e-18 | 8.07e-01 | -0.1954 |
6429 | SRSF4 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.23e-03 | 5.45e-01 | -0.059 |
6429 | SRSF4 | F007 | Human | Colorectum | FAP | 1.83e-02 | -2.20e-01 | 0.1176 |
6429 | SRSF4 | A001-C-207 | Human | Colorectum | FAP | 4.58e-02 | -5.40e-02 | 0.1278 |
6429 | SRSF4 | A015-C-203 | Human | Colorectum | FAP | 7.59e-35 | -3.64e-01 | -0.1294 |
6429 | SRSF4 | A015-C-204 | Human | Colorectum | FAP | 7.66e-10 | -2.91e-01 | -0.0228 |
6429 | SRSF4 | A014-C-040 | Human | Colorectum | FAP | 9.86e-05 | -2.99e-01 | -0.1184 |
6429 | SRSF4 | A002-C-201 | Human | Colorectum | FAP | 4.70e-17 | -2.86e-01 | 0.0324 |
6429 | SRSF4 | A002-C-203 | Human | Colorectum | FAP | 5.06e-08 | -1.95e-01 | 0.2786 |
6429 | SRSF4 | A001-C-119 | Human | Colorectum | FAP | 8.67e-06 | -1.39e-01 | -0.1557 |
6429 | SRSF4 | A001-C-108 | Human | Colorectum | FAP | 1.39e-20 | -1.70e-01 | -0.0272 |
6429 | SRSF4 | A002-C-205 | Human | Colorectum | FAP | 1.14e-25 | -2.40e-01 | -0.1236 |
6429 | SRSF4 | A001-C-104 | Human | Colorectum | FAP | 9.03e-04 | -2.82e-02 | 0.0184 |
6429 | SRSF4 | A015-C-005 | Human | Colorectum | FAP | 3.66e-05 | -1.60e-01 | -0.0336 |
6429 | SRSF4 | A015-C-006 | Human | Colorectum | FAP | 2.50e-19 | -2.85e-01 | -0.0994 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004348410 | Cervix | CC | regulation of RNA splicing | 42/2311 | 148/18723 | 1.25e-07 | 6.24e-06 | 42 |
GO:19033119 | Cervix | CC | regulation of mRNA metabolic process | 64/2311 | 288/18723 | 1.71e-06 | 5.64e-05 | 64 |
GO:003311910 | Cervix | CC | negative regulation of RNA splicing | 13/2311 | 25/18723 | 1.83e-06 | 5.89e-05 | 13 |
GO:004802410 | Cervix | CC | regulation of mRNA splicing, via spliceosome | 28/2311 | 101/18723 | 2.41e-05 | 4.19e-04 | 28 |
GO:00506849 | Cervix | CC | regulation of mRNA processing | 33/2311 | 137/18723 | 1.06e-04 | 1.35e-03 | 33 |
GO:00434349 | Cervix | CC | response to peptide hormone | 77/2311 | 414/18723 | 1.40e-04 | 1.70e-03 | 77 |
GO:190331210 | Cervix | CC | negative regulation of mRNA metabolic process | 24/2311 | 92/18723 | 2.49e-04 | 2.77e-03 | 24 |
GO:000838010 | Cervix | CC | RNA splicing | 76/2311 | 434/18723 | 9.79e-04 | 8.19e-03 | 76 |
GO:00328688 | Cervix | CC | response to insulin | 50/2311 | 264/18723 | 1.28e-03 | 1.02e-02 | 50 |
GO:00480256 | Cervix | CC | negative regulation of mRNA splicing, via spliceosome | 8/2311 | 20/18723 | 1.69e-03 | 1.29e-02 | 8 |
GO:00506866 | Cervix | CC | negative regulation of mRNA processing | 9/2311 | 29/18723 | 6.49e-03 | 3.61e-02 | 9 |
GO:000037710 | Cervix | CC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 55/2311 | 320/18723 | 6.71e-03 | 3.70e-02 | 55 |
GO:000039810 | Cervix | CC | mRNA splicing, via spliceosome | 55/2311 | 320/18723 | 6.71e-03 | 3.70e-02 | 55 |
GO:000037510 | Cervix | CC | RNA splicing, via transesterification reactions | 55/2311 | 324/18723 | 8.61e-03 | 4.44e-02 | 55 |
GO:0008380 | Colorectum | AD | RNA splicing | 169/3918 | 434/18723 | 3.59e-18 | 2.04e-15 | 169 |
GO:0000377 | Colorectum | AD | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 130/3918 | 320/18723 | 5.88e-16 | 2.16e-13 | 130 |
GO:0000398 | Colorectum | AD | mRNA splicing, via spliceosome | 130/3918 | 320/18723 | 5.88e-16 | 2.16e-13 | 130 |
GO:0000375 | Colorectum | AD | RNA splicing, via transesterification reactions | 131/3918 | 324/18723 | 7.11e-16 | 2.22e-13 | 131 |
GO:1903311 | Colorectum | AD | regulation of mRNA metabolic process | 117/3918 | 288/18723 | 1.69e-14 | 4.23e-12 | 117 |
GO:0043484 | Colorectum | AD | regulation of RNA splicing | 70/3918 | 148/18723 | 6.47e-13 | 1.16e-10 | 70 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa03040 | Colorectum | AD | Spliceosome | 73/2092 | 217/8465 | 1.73e-03 | 9.68e-03 | 6.18e-03 | 73 |
hsa030401 | Colorectum | AD | Spliceosome | 73/2092 | 217/8465 | 1.73e-03 | 9.68e-03 | 6.18e-03 | 73 |
hsa0304018 | Esophagus | HGIN | Spliceosome | 79/1383 | 217/8465 | 3.22e-13 | 7.00e-12 | 5.56e-12 | 79 |
hsa0304019 | Esophagus | HGIN | Spliceosome | 79/1383 | 217/8465 | 3.22e-13 | 7.00e-12 | 5.56e-12 | 79 |
hsa0304027 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
hsa0304037 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
hsa030407 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
hsa0304012 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
hsa0304022 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
hsa0304032 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
hsa0304016 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
hsa0304017 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
hsa0304026 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
hsa0304036 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
hsa0304010 | Prostate | BPH | Spliceosome | 62/1718 | 217/8465 | 1.99e-03 | 7.92e-03 | 4.90e-03 | 62 |
hsa0304015 | Prostate | BPH | Spliceosome | 62/1718 | 217/8465 | 1.99e-03 | 7.92e-03 | 4.90e-03 | 62 |
hsa0304025 | Prostate | Tumor | Spliceosome | 66/1791 | 217/8465 | 7.53e-04 | 3.59e-03 | 2.23e-03 | 66 |
hsa0304035 | Prostate | Tumor | Spliceosome | 66/1791 | 217/8465 | 7.53e-04 | 3.59e-03 | 2.23e-03 | 66 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SRSF4 | insertion | Frame_Shift_Ins | novel | c.508dupA | p.Ile170AsnfsTer5 | p.I170Nfs*5 | Q08170 | protein_coding | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD | ||
SRSF4 | SNV | Missense_Mutation | rs368357249 | c.722G>A | p.Arg241Gln | p.R241Q | Q08170 | protein_coding | tolerated(0.08) | benign(0.375) | TCGA-DD-AAE3-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SRSF4 | SNV | Missense_Mutation | c.557N>A | p.Ser186Tyr | p.S186Y | Q08170 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-44-7670-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
SRSF4 | SNV | Missense_Mutation | c.215N>T | p.Gly72Val | p.G72V | Q08170 | protein_coding | deleterious(0.01) | possibly_damaging(0.658) | TCGA-55-8620-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
SRSF4 | SNV | Missense_Mutation | c.548N>T | p.Arg183Leu | p.R183L | Q08170 | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-91-6849-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
SRSF4 | SNV | Missense_Mutation | novel | c.59G>T | p.Arg20Leu | p.R20L | Q08170 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-95-7043-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
SRSF4 | SNV | Missense_Mutation | novel | c.105N>G | p.Asn35Lys | p.N35K | Q08170 | protein_coding | tolerated(0.05) | possibly_damaging(0.859) | TCGA-21-1081-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
SRSF4 | SNV | Missense_Mutation | novel | c.972G>C | p.Glu324Asp | p.E324D | Q08170 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.714) | TCGA-37-4130-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SRSF4 | SNV | Missense_Mutation | novel | c.745N>T | p.Ser249Cys | p.S249C | Q08170 | protein_coding | deleterious(0) | possibly_damaging(0.751) | TCGA-60-2715-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | docetaxel | PD |
SRSF4 | SNV | Missense_Mutation | novel | c.918N>C | p.Glu306Asp | p.E306D | Q08170 | protein_coding | tolerated_low_confidence(0.11) | probably_damaging(0.956) | TCGA-CN-4733-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |